Secondary progressive multiple sclerosis (SPMS) is a second stage of MS that follows relapsing-remitting multiple sclerosis (RRMS). Around 65% of people with RRMS will develop SPMS about 15 years after RRMS diagnosis.

Establishing SPMS diagnosis can be challenging to neurologists because at least six months of progression must be observed before RRMS can be considered secondary progressive. The worsening of symptoms could be due to a relapse that caused permanent but stable damage after an inflammatory attack ended. In that case, the patient is still in the RRMS phase — or there was a worsening of the condition without inflammatory relapses. Repeat brain MRI scans and a neurologic examination can help determine if the disease has actually progressed to SPMS.

SPMS can be characterized as not active, active (with relapses or evidence of new brain MRI lesions), without progression, or with progression (when there is evidence of worsening of the disease over time, with or without relapses).

People diagnosed with SPMS who are on disease-modifying therapies for MS can often continue taking them. The medications include:

Interferon beta (Avonex, Betaseron, Extavia, Plegridy and Rebif)

Teriflunomide (Aubagio)

Fingolimod (Gilenya)

Alemtuzumab (Lemtrada)

Dimethyl fumarate (Tecfidera)

Natalizumab (Tysabri)

One FDA approved chemotherapeutic agent, Novantrone (mitoxantrone) made specifically for SPMS (and for worsening relapsing MS), suppresses the immune system. While there is significant unmet need for SPMS treatments, promising therapies are currently progressing through the research and development pipeline.

There are ways for SPMS patients to help manage the disease. Appropriate exercise and healthy eating habits are important for all people with MS. When relapse or worsening of symptoms occur, physical and occupational therapy can help minimize muscle weakness and help restore movement.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

_________________________

  1. https://www.mssociety.org.uk/what-is-ms/types-of-ms/secondary-progressive-spms
  2. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS/Diagnosing-Secondary-Progressive-MS
  3. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS
  4. http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Secondary-progressive-MS/Treating-Secondary-Progressive-MS

#ECTRIMS2018 – Finding Best Treatment for ‘Right Patient’ and Progressive MS Among Work of Interest, Cleveland Clinic Doctors Say

Tailored, highly effective therapies early in the disease’s course may be a way forward in multiple sclerosis (MS) treatment, according to Cleveland Clinic neurologist Robert Bermel. Another neurologist with the Cleveland Clinic, Robert Fox, talked about potential and upcoming progressive MS treatments.  In interviews with Multiple Sclerosis News Today at the recent 34th congress of the European Committee for […]

SPMS and the Continuum of Acceptance

Some days are hard, while others are still harder. Then there are days that bring you to your knees. I am kneeling. Pain ricochets through my body like a pinball machine on tilt. Flashing lights dance as if to announce the imminent. “Danger, Will Robinson!” I hit the proverbial wall — hard. And it hurts. […]

#ECTRIMS2018 – Blood Level of Neurofilament Light Chain May Predict Brain Atrophy in Progressive MS, Study Suggests

Measuring the blood level of neurofilament light chain (NfL) may predict brain shrinkage in primary progressive (PPMS) and secondary progressive multiple sclerosis (SPMS), according to a new study. The findings also show that NfL levels are associated with brain lesion load in these patients. The research, “Neurofilament light levels in the blood of patients with […]

#ECTRIMS2018 — As Siponimod Awaits FDA Decision, Mouse Work Helps in Understanding Benefits Seen in SPMS

Mouse studies of siponimod — a potential progressive multiple sclerosis (MS) treatment that’s up for approval in the U.S. and EU — were among presentations given by Novartis at the 34th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held Oct. 10-12 in Berlin. Animal work might seem an odd entry at a major science conference, […]

#ECTRIMS2018 — Early Relapses and Larger Lesions Increase Risk of Developing SPMS, Study Reports

A higher frequency of early relapses, as well as a larger volume of lesions and older age at disease onset, increase the risk of transitioning from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive MS (SPMS), according to a study. The study, “Early cortical pathology and early relapses predict the risk of developing secondary progressive MS,” […]

#ECTRIMS2018 – DMTs Slow Down Disability Progression in SPMS Patients with Ongoing Relapses, Analysis Shows

Treatment with disease-modifying therapies (DMTs) may benefit patients with secondary progressive multiple sclerosis (SPMS) who are actively experiencing relapses, as they can slow the disability’s worsening, a new analysis of an MS patient registry shows. Patients who transition early from relapsing-remitting MS (RRMS) to SPMS and those with frequent relapses show a faster accumulation of […]

FDA, EMA Agree to Review Novartis Therapy Siponimod to Treat SPMS

Novartis is seeking U.S. and European approval of its investigational oral agent siponimod to treat adults with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application, while the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application. The FDA is expected […]

Navigating Roadblocks with SPMS

I saw my neurologist earlier this week. After my work-up, we sat and discussed how well I manage my multiple sclerosis. How well? No comment. Suffice it to say this disease is a worthy adversary. I have been feeling a little funky since that appointment. I have been looking to hematopoietic stem cell transplantation (HSCT) […]

MS News that Caught My Eye Last Week: Treating MS with a Statin, Ocrevus, Remyelination

Phase 3 Trial in the UK Soon to Test Statin, Simvastatin, in Slowing SPMS Progression I’ve taken a statin medication for years to keep my cholesterol in check. Now, a study is getting underway to see if one statin pill can also be used to treat MS. It’s particularly encouraging that this med is being […]